QuidelOrtho (QDEL) EVP of R&D & CTO awarded RSUs and 36,150 stock options

Rhea-AI Filing Summary

QuidelOrtho Corporation executive Jonathan Philip Siegrist, EVP of R&D & CTO, reported new equity awards in the form of restricted stock units (RSUs) and stock options. On January 30, 2026, he received 36,152 RSUs, each representing one share of QuidelOrtho common stock, and 36,150 non-qualified stock options with a $27.17 exercise price.

For the RSUs, 12,050 shares are scheduled to vest on January 30, 2027, and the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029. The 36,150 stock options will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029. All awards are reported as directly owned by Siegrist.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Siegrist Jonathan Philip

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP of R&D & CTO

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	01/30/2026		A		36,152		(2)	(2)	Common Stock	36,152	$0	36,152	D
Non-Qualified Stock Options	$27.17	01/30/2026		A		36,150		(3)	01/30/2036	Common Stock	36,150	$0	36,150	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation Common Stock.

2. 12,050 shares will vest on January 30, 2027; the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

3. 36,150 shares will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029.

Remarks:

	/s/ Jennifer Ahn, attorney-in-fact for Jonathan P. Siegrist	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did QuidelOrtho (QDEL) grant to EVP of R&D & CTO Jonathan Siegrist?

QuidelOrtho granted Jonathan Siegrist 36,152 restricted stock units and 36,150 non-qualified stock options. Each RSU represents one share of common stock, and the options have a $27.17 exercise price, creating a significant long-term equity incentive package for the executive.

When do Jonathan Siegrist’s QuidelOrtho (QDEL) restricted stock units vest?

Siegrist’s 36,152 restricted stock units vest over three years. 12,050 shares vest on January 30, 2027. The remaining 24,102 shares vest in equal installments on January 30, 2028 and January 30, 2029, creating a multi-year retention and performance incentive.

What is the vesting schedule for Jonathan Siegrist’s QuidelOrtho (QDEL) stock options?

Siegrist’s 36,150 non-qualified stock options vest in three equal installments. The tranches vest on January 30, 2027, January 30, 2028, and January 30, 2029. This structure encourages continued service and aligns his potential upside with QuidelOrtho’s long-term share performance.

What is the exercise price of Jonathan Siegrist’s new QuidelOrtho (QDEL) stock options?

The non-qualified stock options granted to Jonathan Siegrist carry a $27.17 exercise price per share. He can only benefit financially if QuidelOrtho’s stock trades above this level after vesting, reinforcing alignment between executive rewards and shareholder value creation.

Does Jonathan Siegrist directly own the reported QuidelOrtho (QDEL) equity awards?

Yes. The Form 4 reports both the 36,152 restricted stock units and the 36,150 non-qualified stock options as directly owned. There are no footnotes indicating indirect ownership through entities or any disclaimer of beneficial ownership for these awards.

What role does Jonathan Siegrist hold at QuidelOrtho (QDEL) related to these equity grants?

Jonathan Philip Siegrist serves as QuidelOrtho’s Executive Vice President of Research and Development and Chief Technology Officer. The reported restricted stock units and non-qualified stock options are part of his compensation, tying a portion of his pay to the company’s future performance.